BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer

Recruiting now · Phase 2

Conditions studied: Triple Negative Breast Cancer

In brief

To study the efficacy, safety, pharmacokinetics and immunogenicity of BCD-236 in combination with chemotherapeutic agents (CHT) in 2nd and subsequent lines of therapy of subjects with relapsed and/or metastatic triple negative breast cancer (TNBC).

Key facts

Study ID
NCT07108309
Run by
Biocad
People needed
124
Starts
2024-07-15
Expected to finish
2027-05-01
Last updated by the study team
2025-08-07

Who can join

Age: 18 and older, up to 74. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.